MIRA Pharmaceuticals, Inc. Common Stock (MIRA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has a cash flow conversion efficiency ratio of -0.145x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.10 Million) by net assets ($7.55 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MIRA Pharmaceuticals, Inc. Common Stock (MIRA) market capitalisation for the company's overall valuation and market capitalisation.
MIRA Pharmaceuticals, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how MIRA Pharmaceuticals, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MIRA Pharmaceuticals, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MIRA Pharmaceuticals, Inc. Common Stock ranked by their cash flow conversion efficiency. See MIRA Pharmaceuticals, Inc. Common Stock (MIRA) debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WebCash Corporation
KQ:053580
|
0.049x |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
-0.001x |
|
Juic International
TWO:6114
|
0.032x |
|
Alpha Trust Andromeda Investment Trust S.A
AT:ANDRO
|
0.109x |
|
Doctor Care Anywhere Group Plc
AU:DOC
|
-21.169x |
|
Scandium International Mining Corp
F:0E6
|
0.087x |
|
Yong Shun Chemical Co Ltd
TWO:4711
|
-0.020x |
|
Vext Science Inc
F:VV5
|
0.018x |
Annual Cash Flow Conversion Efficiency for MIRA Pharmaceuticals, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of MIRA Pharmaceuticals, Inc. Common Stock from 2020 to 2024. View MIRA live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $2.20 Million | $-5.56 Million | -2.528x | -143.97% |
| 2023-12-31 | $4.37 Million | $-4.53 Million | -1.036x | -111.02% |
| 2022-12-31 | $-596.23K | $-5.60 Million | 9.400x | +1644.70% |
| 2021-12-31 | $2.26 Million | $-1.38 Million | -0.609x | -160.86% |
| 2020-12-31 | $-67.99K | $-67.99K | 1.000x | -- |
About MIRA Pharmaceuticals, Inc. Common Stock
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling tr… Read more